Q-omics provides the consensus-scored ATP5MC1P5 profile across patient tissues and cancer cell-line models. ATP5MC1P5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ATP5MC1P5 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ATP5MC1P5 RNA expression shows 5,640 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, KIRC, and ESCA as cancer lineages where ATP5MC1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5MC1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5MC1P5 survival associations across molecular data types. ATP5MC1P5 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5MC1P5 RNA expression–survival associations across cancer types. High ATP5MC1P5 expression shows unfavorable associations in BRCA, LIHC and UVM, but favorable associations in HNSC, CESC and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for ATP5MC1P5 RNA expression.
This table summarizes ATP5MC1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5MC1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5MC1P5 shows lower tumor expression in KIRC, KICH, HNSC and KIRP and higher tumor expression in COAD and LIHC. The KIRC box plot shows higher ATP5MC1P5 RNA expression in normal versus tumor tissue (log2 FC = −0.157, t-test p < 0.001).
This table shows molecular features associated with ATP5MC1P5 in patient tissues and cancer cell lines. In patient samples, ATP5MC1P5 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
